Literature DB >> 19414447

From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category.

Jeffrey K Aronson1.   

Abstract

BACKGROUND: Increasing numbers of medicines are being made available over the counter in the UK, by purchase in a pharmacy or from other less well-regulated outlets. When this is allowed by the Licensing Authority, it is often subject to certain restrictions. However, some drugs that could usefully be converted from prescription-only medicines (PoM status) to over-the-counter sales in a pharmacy (P status) are not suitable for full over-the-counter status, even with restrictions; and in some cases restrictions vitiate the usefulness of the medicine. AREAS OF AGREEMENT: Drugs that can acceptably be switched from PoM status to P status include those that are used in the treatment of minor ailments or injuries, for health promotion or in palliative care. AREAS OF CONTROVERSY: However, not all drugs that are being switched fall into these categories. Ready availability of antimicrobial drugs over the counter, one of which (azithromycin) has recently been switched, could encourage the emergence of resistant organisms. Drugs that are used for long-term treatment and lifestyle drugs are also controversial, particularly if their adverse effects are of potential concern. On the other hand, the availability of many drugs via the internet removes the ability of regulators to control the supply of such drugs. A POSSIBLE SOLUTION: A new category of purchase, Pharmacist Consultation and Supply, with built-in safeguards, could improve the availability of some medicines under more careful control than is currently available for over-the-counter medicines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414447     DOI: 10.1093/bmb/ldp015

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  6 in total

1.  Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals.

Authors:  Jayne C Lucke; Stephanie K Bell; Bradley J Partridge; Wayne D Hall
Journal:  EMBO Rep       Date:  2011-02-11       Impact factor: 8.807

2.  Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand.

Authors:  Natalie J Gauld; Fiona S Kelly; Lynne M Emmerton; Stephen A Buetow
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 3.  Role of community pharmacists in patients' self-care and self-medication.

Authors:  Paul Rutter
Journal:  Integr Pharm Res Pract       Date:  2015-06-24

Review 4.  Regulation of Drug Prescribing Information in Latin America and the Caribbean.

Authors:  Mariana Ramírez-Telles; Urimara Argotti-Rodríguez
Journal:  Ther Innov Regul Sci       Date:  2022-04-05       Impact factor: 1.337

5.  A survey of the views and capabilities of community pharmacists in Western Australia regarding the rescheduling of selected oral antibiotics in a framework of pharmacist prescribing.

Authors:  Fatima Sinkala; Richard Parsons; Bruce Sunderland; Kreshnik Hoti; Petra Czarniak
Journal:  PeerJ       Date:  2018-05-07       Impact factor: 2.984

6.  Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling.

Authors:  Natalie J Gauld; Lance C Jennings; Chris Frampton; Q Sue Huang
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.